ABSTRACT

COVID-19: International Trade and Access to Pharmaceutical Products [March 30, 2020]   [open pdf - 549KB]

From the Document: "As the coronavirus disease (COVID-19) pandemic continues, governments and the private sector have begun assessing the possibility of developing medical countermeasures (e.g., vaccines, antiviral treatments) to improve patient recovery rates and contain the virus's spread. Some Members of Congress have expressed concern about access to, and the affordability of, any potential countermeasures. As outlined in this CRS [Congressional Research Service] Sidebar, Congress can take, and has taken, several steps to address these issues, some of which may raise questions under U.S. law. This Sidebar addresses how certain congressional or executive actions intended to increase access to medical countermeasures might be viewed under the rules of the international trade regime, including: (1) exclusion from patent protection; (2) compulsory licensing of patented products; and (3) increasing domestic capacity."

Report Number:
CRS Legal Sidebar, LSB10436
Author:
Publisher:
Date:
2020-03-30
Series:
Copyright:
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations